Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Lirum Therapeutics, Inc.

Lirum Therapeutics Announces FDA “Study May Proceed” Letter Enabling Inclusion of LX-101 in the RAPID Platform Clinical Trial for Ewing Sarcoma and Desmoplastic Small Round Cell Tumor
From Lirum Therapeutics, Inc.
Via GlobeNewswire
Lirum Therapeutics Announces New LX-101 Data in Thyroid Eye Disease Selected for Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
From Lirum Therapeutics, Inc.
Via GlobeNewswire
Lirum Therapeutics’ LX-101 New Positive Data Selected for Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
From Lirum Therapeutics, Inc.
Via GlobeNewswire
Lirum Therapeutics Invited to Present at Prestigious Gordon Research Conference
From Lirum Therapeutics, Inc.
Via GlobeNewswire
Lirum Therapeutics Announces Debut of LX-101 Results in Thyroid Eye Disease, Selected for Presentation at the 2025 NANOS Annual Meeting
From Lirum Therapeutics, Inc.
Via GlobeNewswire
Lirum Therapeutics Presents Positive Data on LX-101 at the 2025 ESMO Targeted Anticancer Therapies Congress; Highlighting LX-101’s Promise in IGF-1R Prominent Cancers
From Lirum Therapeutics, Inc.
Via GlobeNewswire
Lirum Therapeutics to Present Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy Demonstrating Potent Preclinical Activity Against Adult and Pediatric IGF-Related Cancers, at the 2024 AACR Annual Meeting
From Lirum Therapeutics, Inc.
Via GlobeNewswire
Lirum Therapeutics Announces Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy Demonstrating Potent Preclinical Activity Against IGF-Related Cancers, Accepted for Presentation at the 2024 ESMO Sarcoma and Rare Cancers Congres
From Lirum Therapeutics, Inc.
Via GlobeNewswire
Lirum Therapeutics Presents Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy, at the 2024 ESMO Targeted Anticancer Therapies Congress; Highlighting LX-101’s Potential in IGF-1R Prominent Cancers
From Lirum Therapeutics, Inc.
Via GlobeNewswire
Lirum Therapeutics Participates in the 13th Annual LifeSci Partners Corporate Access Event
From Lirum Therapeutics, Inc.
Via GlobeNewswire
Lirum Therapeutics Presents Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy, Demonstrating Potent Preclinical Activity Against Pediatric Sarcomas
From Lirum Therapeutics, Inc.
Via GlobeNewswire
Lirum Therapeutics to Present at the 2023 ThinkEquity Conference
From Lirum Therapeutics, Inc.
Via GlobeNewswire
Lirum Therapeutics Presents Data on LX-101, a Novel Clinical-Stage Targeted Therapy, Demonstrating Potent Preclinical Activity Against a Range of Pediatric Cancers
From Lirum Therapeutics, Inc.
Via GlobeNewswire
Lirum Therapeutics Announces Closing of $7 Million Private Placement of Common Stock
From Lirum Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.